Fulcrum Therapeutics Inc (FULC) Stock Price, Quote & News

Company Profile

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers drug targets for potential treatment inherited aplastic anemias, such...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 651 8851

Website: www.fulcrumtx.com

Address:

26 Landsdowne Street, Cambridge, United States

biochirp Aug. 18 at 12:39 PM

$FULC $XBI https://endpoints.news/pfizers-sickle-cell-drug-candidate-fails-phase-3-trial/?u=0fe66aed-b490-4e96-849f-1f8ad5363ce8&s=email&c=ead60ced-048426a8-90400329&utm_medium=email&utm_campaign=976%20-%20Gene%20therapy%20biotechs%20313M%20raise%20Novos%20Wegovy%20nabs%20MASH%20approval%20Basic&utm_content=976%20-%20Gene%20therapy%20biotechs%20313M%20raise%20Novos%20Wegovy%20nabs%20MASH%20approval%20Basic+CID_7bcdfd025fd420116033241d1ffed7a0&utm_source=ENDPOINTS%20emails&utm_term=Pfizers%20sickle%20cell%20drug%20candidate%20fails%20Phase%203%20trial $PFE

1 · Reply

Kai506 Aug. 6 at 7:04 PM

$FULC Followed in on the massive volume spike. That's not retail money. Possible news leak after market close...I'm hoping

0 · Reply

biochirp Aug. 5 at 1:06 PM

$FULC cmon JNJ now is the time

0 · Reply

StockScanners Aug. 5 at 1:36 AM

$FULC still on watch

0 · Reply

BioTechHealthX Aug. 4 at 2:50 AM

$FULC Pociredir’s strong efficacy, clean safety, and massive potential market make Fulcrum one of the most exciting biotech plays right now. https://biotechhealthx.com/biotech-news/fulcrum-therapeutics-fulcs-stunning-trial-results-could-make-it-the-next-biotech-breakout/

0 · Reply

StockScanners Aug. 2 at 6:29 PM

$FULC needs to hold above 6

0 · Reply

edvquye Aug. 1 at 5:37 PM

$FULC in here

0 · Reply

alfafc Jul. 30 at 4:52 PM

$FULC

0 · Reply

JarvisFlow Jul. 30 at 2:27 PM

RBC Capital updates rating for Fulcrum Therapeutics ( $FULC ) to Sector Perform, target set at 4 → 5.

0 · Reply

Dkll303 Jul. 30 at 12:22 PM

$AGIO $FULC Good olé HC WAINWRIGHT…sucking in investors to FULC …hahahaha .. Still at it …copy cat of LUTNICK- Cantor Fitz and his pathetic “ outperforms “ that DIE and never go any where …AGIO

0 · Reply

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 29, 2025, 6:48 AM EDT - 26 days ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025

Jul 29, 2025, 6:45 AM EDT - 26 days ago

Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

Jul 28, 2025, 4:01 PM EDT - 27 days ago

Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

May 29, 2025, 4:10 PM EDT - 3 months ago

Fulcrum Therapeutics to Present at Upcoming Medical Meetings

May 29, 2025, 8:30 AM EDT - 3 months ago

Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

May 8, 2025, 4:05 PM EDT - 3 months ago

Fulcrum Therapeutics to Participate in Upcoming May Conferences

May 1, 2025, 1:55 PM EDT - 4 months ago

Fulcrum Therapeutics, Inc. (FULC) Q1 2025 Earnings Call Transcript

May 1, 2025, 7:00 AM EDT - 4 months ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025

Apr 24, 2025, 8:00 AM EDT - 4 months ago

Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET

Mar 4, 2025, 4:05 PM EST - 6 months ago

Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference

Feb 25, 2025, 10:58 PM EST - 6 months ago

Fulcrum Therapeutics, Inc. (FULC) Q4 2024 Earnings Call Transcript

Feb 25, 2025, 7:00 AM EST - 6 months ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024

Feb 18, 2025, 4:05 PM EST - 6 months ago

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET

Feb 6, 2025, 4:05 PM EST - 7 months ago

Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Nov 26, 2024, 4:05 PM EST - 9 months ago

Fulcrum Therapeutics to Participate in Upcoming December Conferences

Nov 13, 2024, 7:48 PM EST - 10 months ago

Fulcrum Therapeutics, Inc. (FULC) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:05 PM EST - 10 months ago

Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference

Nov 6, 2024, 8:00 AM EST - 10 months ago

Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET

Oct 7, 2024, 2:03 PM EDT - 11 months ago

FMR LLC's Strategic Reduction in Fulcrum Therapeutics Inc Shares

Oct 2, 2024, 6:30 PM EDT - 11 months ago

Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Fulcrum Therapeutics Inc For Possible Securities Fraud

Oct 1, 2024, 6:15 PM EDT - 11 months ago

Fulcrum Therapeutics, Inc. Is Being Investigated For Violating Securities Laws And The Schall Law Firm Urges Shareholder Participation

Sep 30, 2024, 8:00 PM EDT - 11 months ago

Investors Are Encouraged To Join The Schall Law Firm In An Inquiry Into Fulcrum Therapeutics Inc For Possible Securities Fraud

Sep 28, 2024, 8:00 PM EDT - 11 months ago

The Schall Law Firm Is Looking Into Whether Fulcrum Therapeutics Inc Committed Securities Fraud And Impacted Investors Should Reach Out

Sep 27, 2024, 6:30 PM EDT - 11 months ago

Shareholders Are Encouraged To Join The Schall Law Firm's Inquiry Into Fulcrum Therapeutics, Inc. For Violating Securities Laws

Sep 27, 2024, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulcrum Therapeutics, Inc. (FULC) And Encourages Shareholders to Reach Out

Sep 26, 2024, 6:40 PM EDT - 11 months ago

Fulcrum Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Investors To Lend A Hand

Sep 26, 2024, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulcrum Therapeutics, Inc. (FULC) and Encourages Shareholders to Learn More About the Investigation

Sep 25, 2024, 10:00 AM EDT - 11 months ago

Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Sep 24, 2024, 6:00 PM EDT - 11 months ago

Fulcrum Therapeutics Inc May Have Defrauded The Public And Affected Investors Should Join The Schall Law Firm's Inquiry

Sep 24, 2024, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Fulcrum Therapeutics, Inc. (FULC) Shareholders to Inquire about Securities Investigation

biochirp Aug. 18 at 12:39 PM

1 · Reply

Kai506 Aug. 6 at 7:04 PM

$FULC Followed in on the massive volume spike. That's not retail money. Possible news leak after market close...I'm hoping

0 · Reply

biochirp Aug. 5 at 1:06 PM

$FULC cmon JNJ now is the time

0 · Reply

StockScanners Aug. 5 at 1:36 AM

$FULC still on watch

0 · Reply

BioTechHealthX Aug. 4 at 2:50 AM

0 · Reply

StockScanners Aug. 2 at 6:29 PM

$FULC needs to hold above 6

0 · Reply

edvquye Aug. 1 at 5:37 PM

$FULC in here

0 · Reply

alfafc Jul. 30 at 4:52 PM

$FULC

0 · Reply

JarvisFlow Jul. 30 at 2:27 PM

RBC Capital updates rating for Fulcrum Therapeutics ( $FULC ) to Sector Perform, target set at 4 → 5.

0 · Reply

Dkll303 Jul. 30 at 12:22 PM

0 · Reply

Quantumup Jul. 30 at 12:10 PM

H.C. Wainwright yesterday⬆️ $FULC to Buy-$12 from Neutral-$4. $PFE $VRTX $QURE SGMO $AGIO CRSP BLUE - CG H.C. Wainwright said, "Today's 12mg dataset from Fulcrum's PIONEER Phase 1b trial builds meaningfully on prior mechanistic and early clinical observations, offering a tangible glimpse into the translational potential of HbF induction in sickle cell disease (SCD). We view the absolute increase in fetal hemoglobin (HbF), combined with improvements in key hematologic and hemolytic parameters, as validation of pociredir's ability to recapitulate the protective biology observed in hereditary persistence of fetal hemoglobin (HPFH). This matters clinically because patients with HPFH exhibit far fewer vaso-occlusive complications despite possessing the same ß-globin mutation. H.C. Wainwright additionally said:

0 · Reply

d_risk Jul. 30 at 4:30 AM

$FULC - Fulcrum Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors FULC’s 10-Q reveals heightened risks from ongoing operating losses, Phase 3 failure-driven R&D cuts, clinical and regulatory uncertainties, intensified IP and commercialization challenges, new tax and pricing pressures, expanded compliance and cybersecurity risks, and concentrated ownership with anti-takeover measures. #Biotechnology #FinancialRisk #IntellectualProperty #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/FULC/10-Q/2025-07-29

0 · Reply

alfafc Jul. 29 at 3:39 PM

$FULC 8?

0 · Reply

_www_larval_com_ Jul. 29 at 2:42 PM

$FULC just stumbled -4% lower to -7% (~5Mv) moments ago, 08/15 options, follow for more volatility.

0 · Reply

biochirp Jul. 29 at 2:14 PM

$FULC guys the data was actually good

0 · Reply

NSAR Jul. 29 at 2:10 PM

$FULC very positive comments from the very first analyst since the release!!!!!

0 · Reply

Lets_Go_Brndn Jul. 29 at 2:05 PM

$FULC

0 · Reply

NSAR Jul. 29 at 1:59 PM

$FULC from what I’m reading is all positive. The stock was up close to 30% premarket and then sold off and it was down 20% premarket and now it’s back to even. The first analyst comment, reiterated, outperform, and raise the price target. The company is flooded with cash four dollars per share no debt.

0 · Reply

theoptionsplug Jul. 29 at 1:52 PM

$FULC CLINICAL TRIALS: PROMISING PHASE 1B RESULTS FOR SICKLE CELL DRUG 💊

0 · Reply

paddypablo Jul. 29 at 1:13 PM

$FULC ✈️✈️🙌🙌🙌

0 · Reply

biolevity Jul. 29 at 1:13 PM

Initial reaction to $FULC data were -ve, but after the call the stock has rebounded. Think this is going higher....

0 · Reply

Market Cap	372.15M
Revenue (ttm)	80.00M
Net Income (ttm)	-9.73M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-12.16%
Debt to Equity Ratio	0.00

Volume	362,200
Avg Vol	728,494
Day's Range	N/A - N/A
Shares Out	54.09M
Stochastic %K	74%
Beta	2.47
Analysts	Strong Sell
Price Target	$11.07